Bank loans aren't the cure-all for rising rates

They don't get much of a benefit unless short-term rates rise, Schwab strategist says
JUN 04, 2013
No bond sector has been hotter than bank loans this year, but investors who are loading up on them to protect from rising interest rates may be disappointed. Bank loan mutual funds had more than $19 billion in net inflows this year through the end of April, the most of any bond fund category and up from $1.26 billion a year earlier, according to Morningstar Inc. The loans have become popular thanks to their floating rates, which typically are tied to benchmarks such as the London Interbank Offered Rate. The only problem is that those benchmarks are tied to short-term rates, while the market is being driven by long-term rates, said Kathy Jones, a fixed-income strategist at The Charles Schwab Corp. “Bank loans aren't necessarily a bad idea, but they're not going to deliver the returns people are hoping for until short-term rates go up,” she said. “They're not going to get a lot of benefit from long-term rates rising.” Last month, long-term rates skyrocketed 25% to 2.13%, from 1.66% at the beginning of the month, as investors worried about the Federal Reserve slowing down its asset purchasing program this year. The violent jerk upward caused losses across every bond fund category at Morningstar except bank loans, which finished the month virtually flat. The outperformance, however, is largely thanks to their relatively high yields and the fact that they are short-term bonds, rather than benefiting from rising rates, Ms. Jones said. “Bank loans may not hurt you, but they may not help, either,” she said. “We don't want people to be disappointed.” Bank loans won't see a benefit from rising rates until the Fed starts moving short-term interest rates, which it has kept near zero since 2008. Such a move is incredibly unlikely as long as quantitative easing is still going on, Ms. Jones said.

Latest News

GLP-1 users are trading retirement savings for their prescriptions
GLP-1 users are trading retirement savings for their prescriptions

A Nationwide survey finds 47% of GLP-1 users have never discussed the drugs’ financial impact with an advisor, even as many dip into savings.

Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors
Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors

The hundreds of millions of dollars from a sale of Inspired Healthcare properties does not mean an immediate windfall for investors.

Class action alleges Webull misled investors about China operations
Class action alleges Webull misled investors about China operations

Its SEC filings said one thing - a congressional probe said another.

Investors accuse Netcapital of inflating revenue through sham deals
Investors accuse Netcapital of inflating revenue through sham deals

Sham agreements allegedly padded revenue by 345%.

Pre-retirees are looking for flexibility, security, and guidance when it comes to retirement income: Cerulli
Pre-retirees are looking for flexibility, security, and guidance when it comes to retirement income: Cerulli

"Most pre-retirees are uncomfortable making key retirement income decisions without an advisor's help," said Chris Bailey of Cerulli.

SPONSORED Built on insurance experience to deliver on long-term promises

Knighthead Life entered the market with a competitive MYGA. A strong launch earned advisor confidence and paved the way for FIAs.

SPONSORED In the Age of AI, Trust Becomes the Advisor's Greatest Asset

As AI makes financial information more accessible than ever, Lana Hock explains why human judgment, trust, and empathy remain the qualities clients value most in a financial advisor